Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ
Alzheimer’s disease
TGF-β1
amyloid-β
antidepressants
depression
fluoxetine
memory
vortioxetine
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
04
2019
accepted:
28
05
2019
entrez:
12
7
2019
pubmed:
12
7
2019
medline:
12
7
2019
Statut:
epublish
Résumé
Depression is a risk factor for the development of Alzheimer's disease (AD), and the presence of depressive symptoms significantly increases the conversion of mild cognitive impairment (MCI) into AD. A long-term treatment with antidepressants reduces the risk to develop AD, and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently being studied for their neuroprotective properties in AD. In the present work, the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype induced by intracerebroventricular injection of amyloid-β (1-42) (Aβ
Identifiants
pubmed: 31293421
doi: 10.3389/fphar.2019.00693
pmc: PMC6598642
doi:
Types de publication
Journal Article
Langues
eng
Pagination
693Références
J Cell Sci. 2003 Jan 15;116(Pt 2):217-24
pubmed: 12482908
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10417-22
pubmed: 12925731
Arch Neurol. 2004 Aug;61(8):1290-3
pubmed: 15313849
Int Immunopharmacol. 2006 Aug;6(8):1298-304
pubmed: 16782542
J Clin Invest. 2006 Nov;116(11):3060-9
pubmed: 17080199
J Clin Psychopharmacol. 2007 Feb;27(1):67-70
pubmed: 17224716
J Neurosci. 2007 Mar 14;27(11):2948-57
pubmed: 17360918
Behav Pharmacol. 2007 Sep;18(5-6):507-13
pubmed: 17762519
Clin Dev Immunol. 2007;2007:76396
pubmed: 18317531
Neurobiol Dis. 2008 May;30(2):234-42
pubmed: 18356065
J Affect Disord. 2009 Sep;117(1-2):24-9
pubmed: 19138799
J Neurosci. 2009 Aug 26;29(34):10582-7
pubmed: 19710311
CNS Neurosci Ther. 2011 Aug;17(4):237-49
pubmed: 19925479
Learn Mem. 2009 Dec 22;17(1):5-11
pubmed: 20028732
Br J Pharmacol. 2010 Apr;159(8):1704-15
pubmed: 20218978
Neurobiol Aging. 2012 Jul;33(7):1329-42
pubmed: 21414686
Curr Protoc Neurosci. 2011 Apr;Chapter 8:Unit 8.10A
pubmed: 21462162
Brain Behav Immun. 2011 Nov;25(8):1582-91
pubmed: 21640817
J Affect Disord. 2011 Nov;134(1-3):217-25
pubmed: 21684012
Eur Neuropsychopharmacol. 2012 Apr;22(4):281-9
pubmed: 21924590
J Pharmacol Exp Ther. 2012 Mar;340(3):666-75
pubmed: 22171087
J Alzheimers Dis. 2013;33 Suppl 1:S49-65
pubmed: 22785404
Curr Opin Psychiatry. 2012 Nov;25(6):457-61
pubmed: 22801361
Mol Psychiatry. 2013 Oct;18(10):1053-4
pubmed: 23183490
Curr Pharm Des. 2014;20(15):2491-505
pubmed: 23859553
Pharmacol Ther. 2015 Jan;145:43-57
pubmed: 25016186
Eur J Pharmacol. 2015 Apr 15;753:19-31
pubmed: 25107284
Curr Alzheimer Res. 2014;11(7):672-80
pubmed: 25115542
Neuropharmacology. 2015 Feb;89:382-90
pubmed: 25446573
J Alzheimers Dis. 2015;45(3):907-19
pubmed: 25633681
Neurobiol Aging. 2015 Jun;36(6):2043-52
pubmed: 25862419
Eur Neuropsychopharmacol. 2015 Aug;25(8):1353-61
pubmed: 25914158
Pharmacol Biochem Behav. 2015 Aug;135:70-82
pubmed: 26046533
Sci Rep. 2015 Jun 10;5:11252
pubmed: 26059637
Int J Geriatr Psychiatry. 2016 Aug;31(8):920-8
pubmed: 26766490
Psychopharmacology (Berl). 2016 May;233(9):1623-36
pubmed: 26803500
Pharmacol Res. 2016 Apr;106:10-20
pubmed: 26875816
Eur Neuropsychopharmacol. 2016 Jun;26(6):979-93
pubmed: 27139079
Neuroscience. 2016 Aug 25;330:326-34
pubmed: 27268280
Int J Neuropsychopharmacol. 2016 Aug 24;:null
pubmed: 27312740
Mol Neurobiol. 2017 Aug;54(6):4160-4171
pubmed: 27324897
Behav Brain Res. 2016 Nov 1;314:106-15
pubmed: 27498145
Front Pharmacol. 2016 Oct 25;7:389
pubmed: 27826242
J Neurosci. 2016 Nov 30;36(48):12106-12116
pubmed: 27903721
Int J Neuropsychopharmacol. 2017 Jun 1;20(6):510-515
pubmed: 28158336
EJNMMI Res. 2017 Dec;7(1):24
pubmed: 28324341
Oncotarget. 2017 Apr 25;8(17):27676-27692
pubmed: 28430602
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Aug 1;78:114-122
pubmed: 28499898
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt B):123-131
pubmed: 28533150
J Neurosci. 2017 Jul 12;37(28):6797-6809
pubmed: 28607171
Eur J Pharmacol. 2017 Dec 15;817:30-37
pubmed: 28625569
Curr Alzheimer Res. 2018 Feb 22;15(4):363-380
pubmed: 28847284
Neuropharmacology. 2017 Nov;126:200-212
pubmed: 28911966
Alzheimers Dement (N Y). 2017 Aug 05;3(3):440-449
pubmed: 29067350
Pharmacol Res. 2018 Apr;130:374-384
pubmed: 29438781
Front Pharmacol. 2018 Mar 06;9:162
pubmed: 29559911
Can J Psychiatry. 2019 Jan;64(1):18-29
pubmed: 29685068
Neuropharmacology. 2018 Aug;138:151-159
pubmed: 29885420
Brain Behav Immun. 2018 Oct;73:533-545
pubmed: 29935310
Dement Geriatr Cogn Disord. 2018;46(3-4):140-153
pubmed: 30199883
Prog Neurobiol. 2019 Apr;175:35-53
pubmed: 30593839
Cells. 2019 Jan 17;8(1):null
pubmed: 30658430
Eur J Pharmacol. 1978 Oct 1;51(3):291-4
pubmed: 568552
Brain Res. 1996 Jan 15;706(2):181-93
pubmed: 8822355